Prolonged thrombocytopenia after allogeneic haematopoietic stem cell transplantation (HSCT) is reported in approximately 20-40% of patients, with a negative impact on survival. [1] [2] [3] With the exception of thrombocytopenia due to disease recurrence, prolonged thrombocytopenia after HSCT is multifactorial, with several risk factors including number of HLA mismatches, graft loss, infectious complications (particularly CMV or other herpes virus-related infections or reactivation), secondary microangiopathy (following utilization of calcineurin inhibitors) and GvHD. 4, 5 Thrombocytopenia can occur as secondary failure of platelet recovery (SFPR), defined as a decline in platelet counts below 20 000/μL for 7 consecutive days, or requiring transfusion support after achieving sustained counts ⩾ 50 000/μL without transfusions for 7 consecutive days after HSCT. 6 Furthermore, long-lasting thrombocytopenia could lead to potentially lethal bleeding, thus necessitating the use of prophylactic or therapeutic platelet transfusions. Currently, there is a lack of effective and reliable methods to promote platelet engraftment, and to prevent hemorrhagic complications and platelet transfusion needs in HSCT recipients. The use of the SC recombinant TPO agonist romiplostim could be an attractive option, but many concerns still exist about its safety and feasibility after HSCT.
To investigate this issue, we report on eight patients receiving romiplostim after HSCT for secondary thrombocytopenia not related to disease relapse. Baseline characteristics are summarized in Table 1 . All patients underwent HSCT for high-risk hematological malignancies (five acute myeloid leukemia, one myelodysplastic syndrome, one non-Hodgkin lymphoma and one T-cell leukemia/lymphoma). Six out of eight patients were in CR at the time of HSCT. Two patients had received a previous HSCT, one of which was an autologous HSCT. Median age at transplant was 53 years (range 16-67). Median platelet count before HSCT was 87 000/μL (range 24 000-159 000/μL).
Five patients received PBSC from haploidentical donors, one from an HLA-identical sibling, one from a matched unrelated donor and one patient was transplanted using a single cord blood unit.
A reduced toxicity conditioning regimen was used in all patients, with three receiving a combination of thiotepa, etoposide and cyclophosphamide followed by fludarabine and busulfan-based reduced intensity conditioning (Sequential schema). In a total of five patients, in vivo T-cell depletion with rabbit antithymocyte globulin at a total dose of 5 mg/kg was used. All patients received cyclosporine-based prophylaxis for GvHD, with the addition of mycophenolate mophetil in cases with unrelated or haploidentical donors. In addition, patients undergoing haploidentical HSCT received two doses of cyclophosphamide (50 mg/kg) at days +3 and +5.
All patients achieved neutrophil engraftment with full donor chimerism, at a median time of 17 days (range 10-26). Five out of eight patients were evaluable for platelet engraftment, occurring at a median of 11 days after HSCT (range 9-41). The remaining three patients did not meet platelet engraftment criteria as they received daily therapeutic platelet transfusions to control active hemorrhagic complications, due to BK polyomavirus (BK) virus hemorrhagic cystitis (HC). HC occurred in five out of the eight patients, and was classified according to the standard criteria 7, 8 as grade 3 in two patients and grade 4 in three patients. The treatment consisted of hyperhydration, intravenous immunoglobulin, continuous bladder irrigation, antispasmodic and pain management in all HC cases, with four patients receiving cidofovir treatment. The two most severe cases required clot evacuation under cystoscopy.
Use of romiplostim in our patients ( Table 2 ) was required because of two main complications: (a) SFPR with periodic prophylactic platelet transfusion, (b) hemorrhagic complications (mainly BK virus HC) with daily therapeutic transfusion needs. Five patients had decreased marrow megakaryocytes before romiplostim treatment was initiated, suggesting impaired platelet production. Romiplostim treatment was started at medians of 23 and 32 days after onset of SFPR or hemorrhagic complications, respectively. The starting dose was, in most cases (n = 5), 3 μg/kg weekly, except in three patients, two of whom started at 1 μg/kg and the remaining one at 4 μg/kg.
Three patients developed SFPR, at a median of 151 days after HSCT (range 132-322). Dose escalation by 1 μg/kg per week until the maximal authorized dose of 10 μg/kg was made until the recovery of platelets (450 000/μL), with no dose adjustment when platelet were between 50 000/μL and 100 000/μL. With a median of two injections, platelet recovery occurred in all SFPR: one patient achieved response after the second injection, but dose escalation up to 10 μg/kg was needed in order to reach platelets ⩾ 100 000/μL required for proceeding to surgery. Romiplostim was then discontinued after a total of 17 injections. The other two patients achieved responses after the first and the fifth injection, respectively, with drug discontinuation after 5 and 14 injections, respectively. No patient developed recurrence of thrombocytopenia after romiplostim discontinuation. A similar dose escalation of 1 μg/kg per week was used in the five hemorrhagic patients until reduction in platelet transfusion needs and hemorrhagic recovery. Doses were escalated to a maximum of 10 μg/kg in two patients. Transfusion needs did not significantly change with romiplostim, and resolution of HC was observed in three out of five patients. The median time to hemorrhage recovery for the three evaluable patients was 44 days (range 9-106), after a median of four injections. The remaining two patients died, one due to a disseminated multiresistant HSV infection and the other of a Pseudomonas Aeruginosa pneumonia concomitant to a grade IV steroid-refractory GvHD. They received a total of seven injections and five injections, respectively. Pancytopenia related to poor graft function was observed in two hemorrhagic patients, who then underwent a CD34+ cell selected boost, with an achievement of platelet recovery 3 weeks later, followed by romiplostim discontinuation. Timing to hematological recovery was similar to what has already been reported. 5, 9 However, romiplostim was reintroduced in one of Letter to the Editor those patients (number 2), due to recurrent thrombocytopenia after a short period (total 137 days, lasting 14 days after romiplostim withdrawal) of platelet recovery. Interestingly, one could argue that, in this patient, previously not responding to romiplostim, the use of the drug after the selected CD34+ cell boost could have enhanced megakaryocytic differentiation creating a favorable microenvironment. In our series, transplant-related complications and their respective treatments may also have contributed to low platelet counts because of increased consumption. These included viral complications such as CMV reactivation in six out of eight patients (occurring in one patient before thrombocytopenia onset and later in the other five patients, Table 2 ), with five patients experiencing CMV recurrences (median 3) after treatment with ganciclovir or foscarnet.
One patient developed disseminated infection due to HSV infection resistant to antiviral treatments (valaciclovir and cidofovir). Six patients developed other concomitant infectious complications, mostly of bacterial origin.
Other transplant-related complications, including acute GvHD, occurred in five patients (three grade III-IV and two grade I-II). Two cases of steroid-refractory aGvHD were treated with methotrexate followed by inolimumab, and with rituximab, respectively. In both cases, concomitant signs of thrombotic microangiopathy were observed, leading to cyclosporine A withdrawal.
Six out of eight patients were alive at median follow-up of 317 (range 119-623) and of 181 days (range 74-307) after HSCT and romiplostim start, respectively. All patients were in CR with a full donor chimerism at last disease evaluation. No patient needed drug discontinuation related to the onset of adverse events.
Some concerns had been raised about the risk of thrombotic complications and disease relapse in patients undergoing romiplostim administration; however, we demonstrate the safety of romiplostim treatment after HSCT. 10, 11 The occurrence of SFPR concomitantly with GvHD and/or infectious complications, together with the toxicity of the treatment, especially in the setting of haploidentical HSCT are in line with previous reports. 6 Romiplostim treatment is effective especially in patients with SFPR, reducing transfusion needs and hemorrhagic risk. In hemorrhagic patients, we cannot exclude that hemorrhage recovery was accelerated by romiplostim use, but we cannot draw a definitive conclusion given the low number of patients and the presence of several concomitant factors. Despite the limited number of patients in our series, it seems safe to start at a dose of 3 μg/kg in order to more rapidly stimulate the residual megakaryocytic component in transplanted patients.
Our results support the use of this agent in patients with prolonged thrombocytopenia after HSCT and open the discussion for the design of a prospective study to assess its safety, efficacy and best dosing or schedules. Further studies are needed to investigate the potential use of romiplostim after day 100. Moreover, further investigation is also warranted to assess whether romiplostim may enhance the long-term efficacy of a CD34+ cell selected boost in such patients. Abbreviations: BM = bone marrow; d = day; HC = hemorrhagic cystitis; HSCT = hematopoietic stem cell transplantation; MK = megakaryocytes; NA = not applicable; PLT = platelets; Rm = romiplostim; SFPR = secondary failure platelet recovery; TTP = thrombotic thrombocytopenic purpura; UPN = unique patient number.
a CMV reactivation after HSCT presenting with the nearest timing to thrombocytopenia occurrence.
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